Agendia

Genomic assays have evolved to answering more than ‘Does my patient need chemo or not?’ Recent data shows that MammaPrint? and BluePrint? together can help clinicians answer multiple therapy escalation questions off one core biopsy sample. If you're attending the San Antonio Breast Cancer Symposium (SABCS) and want to learn more about this data, join William Audeh, MD, MS, Chief Medical Officer of Agendia, for an Exhibitor Product Theater on Wednesday, December 11th. The one-hour Product Theater titled, “How can genomic information from a single core biopsy sample inform multiple therapy decisions for early-stage ER+ Breast cancer?,” will be taking place in Product Theatre A. To register, visit https://bit.ly/40Bv5js #BreastCancerResearch #SABCS2024 #MammaPrint #BluePrint

#DYK: Neoadjuvant chemotherapy refers to chemotherapy that is given before surgery? The goal of neoadjuvant chemotherapy is to shrink the tumor or reduce its spread, making it easier to remove surgically, or to improve the success of the surgery by reducing the size of the cancer. The number of neoadjuvant chemotherapy cycles will vary from patient to patient and will be based on individual factors, such as tumor size, stage, receptor status, and response to the first few cycles of chemotherapy. If it has been determined that neoadjuvant chemotherapy is appropriate for you or a loved one diagnosed with breast cancer, please know this therapy can be a powerful tool in the treatment of your specific tumor type, leading to better surgical and long-term survival outcomes. For more about neoadjuvant chemotherapy, read our blog post at https://lnkd.in/gjm8cJc9 #Agendia #Chemotherapy #BreastCancer

Agendia announced we will be presenting new data on our early-stage breast cancer genomic tests and their ability to inform treatment selection decisions at the San Antonio Breast Cancer Symposium (SABCS)! The presented data highlights Agendia’s continued focus on expanding clinical utility of the tests and optimizing breast cancer management throughout the patient’s treatment journey. These studies further enhance robust body of clinical research supporting the utility of MammaPrint? and Blueprint? in providing reliable guidance for therapeutic decisions in early-stage breast cancer. To learn more, visit: https://bit.ly/4i4nAYI #SABCS2024 #BreastCancerResearch #MammaPrint #BluePrint

Are you ready to learn more about how MammaPrint? and BluePrint? are changing the landscape of treatment decisions for early-stage breast cancer patients? Our genomic tests use a single core biopsy sample to provide clinicians with valuable information that can guide therapy decisions for early-stage, ER+ breast cancer. Don’t miss William Audeh, MD, MS, Chief Medical Officer of Agendia, as he presents, “How can genomic information from a single core biopsy sample inform multiple therapy decisions for early-stage ER+ Breast cancer?” on Wednesday, December 11 in Product Theatre A at the San Antonio Breast Cancer Symposium (SABCS). Register to attend at https://lnkd.in/gY7JXhAK and learn how these advanced genomic assays are transforming personalized breast cancer care. #BreastCancerResearch #SABCS2024 #MammaPrint #BluePrint?

Together, our MammaPrint? and BluePrint? tests help multidisciplinary care teams better counsel patients on the best possible treatment options for their breast cancer. Choosing more effective treatment approaches can improve patient outcomes and quality of life. Our genomic tests allow physicians to examine the activity of specific genes inside a tumor. By pairing these insights with clinicopathologic factors, we can more comprehensively understand a woman’s unique cancer and more confidently plan her next steps. To hear more insights from Agendia and receive the latest news, subscribe to our Healthcare Provider Newsletter at https://lnkd.in/gjHd6hSg

Agendia’s Co-Founder, Laura van 't Veer, PhD, will be opening the Antoni van Leeuwenhoek's Symposium: 30 Years of Moceular Diagnostics in the AVL, as the keynote speaker! Dr. van 't Veer’s collaboration with The Netherlands Cancer Institute (NKI) over the past 30 years has been crucial to advances in the field of molecular diagnostics, particularly in breast cancer care. Dr. van ‘t Veer co-founded the molecular diagnostics platform at the NKI, which led to the development of Agendia’s MammaPrint? 70-gene assay, and has helped improve quality of life for thousands of patients worldwide. For more information on the symposium and Dr. van ‘t Veer’s lecture, visit https://bit.ly/4erVCTO

Thank you to Healthcare Tech Outlook for recognizing Agendia as one of the Top 10 Precision Oncology Solutions Providers in 2024! We are proud to be a part of the precision medicine movement with our genomic tests, MammaPrint? and BluePrint?, for early-stage breast cancer. To read more about the recognition, our fellow nominees, and trends in the global precision medicine market, visit https://lnkd.in/gGFaqzAt #Agendia #BreastCancerResearch #PrecisionMedicine #Oncology

Prior to genomic profiling, breast cancer treatment decisions were based solely on clinicopathologic factors – such as the patient’s age, tumor grade, lymph node involvement, and hormone receptor status. While important to consider, they provide a more superficial view of the patient’s breast cancer. Now we know that breast cancer is really not one disease. Sheldon Feldman, MD, Chief Division of Breast Surgery and Breast Surgical Oncology, Director, Breast Cancer Services, Professor, Department of Surgery, Montefiore Einstein, discusses that there are different subtypes of breast cancer that have different prognoses and recommended treatment methods. “We have two sides to the equation. We have the biology and the stage of the cancer and then we have the medical specifics of the patients – if they're young or they're old, have they had children or not, do they have other health problems? And all [of] this really gets considered when an individual treatment plan is decided upon.” Our genomic tests, MammaPrint? and BluePrint?, provide information on the activity of specific genes inside a tumor. By pairing these insights with clinical factors, we can more comprehensively understand a woman’s unique cancer and more confidently plan her next steps. For more, visit https://bit.ly/4f4xnMj for Dr. Feldman’s interview with OncLive.

#JADPROLive2024 is here! We're excited to join our industry colleagues at this year’s Advanced Practitioner Society For Hematology And Oncology (APSHO)’s annual meeting! Visit Agendia at Booth #1219 to learn more about how we deliver breakthrough genomic tests that improve quality of life for early-staged breast cancer patients. For more information about the meeting schedule, visit: https://jadprolive.com/ #APSHO #Oncology #Hematology

Join Agendia in congratulating Professor Laura van 't Veer, Co-Founder of Agendia, pioneer in personalized cancer care and co-developer of the MammaPrint? genomic breast cancer recurrence test, for being honored for her work in molecular cancer diagnostics and breast cancer research over the past 30 years! She is receiving the Luigi Castagnetta Award in Cancer Research, today, November 14th, in Sicily. This award recognizes researchers not only for their exceptional contributions to understanding and treating cancer, but also their cutting-edge research for cancer therapies. She will also be the keynote lecture at the Amsterdam Antoni van Leeuwenhoek Hospital's anniversary symposium, "30 Years of Molecular Diagnostics at the AVL," on November 19th in Amsterdam and is receiving the William L. McGuire Memorial Lecture Award at the San Antonio Breast Cancer Symposium on December 11th in San Antonio. Learn more about the awards and Dr. van ‘t Veers’ pioneering work: https://bit.ly/4erVCTO #BreastCancerResearch #MammaPrint